Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bronchodilator · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Bronchodilator | DRUG | - |
Inclusion Criteria: * Persistent asthma for a minimum of six months duration that has been stable for at least four weeks * Predicted FEV1 60-90% * Demonstration of 12% airway reversibility Exclusion Criteria: * Continuous requirement for beta-blockers, monoamine oxidase (MAO) inhibitors, tricycl...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Bronchodilator is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 2 clinical development and is being studied in pediatric patients with asthma.
Bronchodilator is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker TEVA. The drug is currently in Phase 2 clinical trials for asthma.
Bronchodilator is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial for the drug has been completed.
Bronchodilator has one completed Phase 2 clinical trial with the identifier NCT00112411, titled 'Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics'. The trial was conducted in the United States and enrolled pediatric patients aged 4 years and older with asthma.
Bronchodilator is the name used for the drug in clinical development. No alternative names have been established for this investigational product.